Innovative platforms and engineering approaches have created the next generation of bispecific antibodies with novel functionalities and features. However, the challenge is to identify attributes early in the process to make necessary improvements to constructs and avoid failures in the clinic late in the development process. Join this year’s leading experts as we explore one of the most exciting areas in biologics and discover what the newest platforms and engineering approaches are that promise an increasingly diverse array of new constructs and strategies that can achieve unprecedented efficacy.

For more details on the conference, please contact:

Christina Lingham
Executive Director, Conferences and Fellow
Cambridge Healthtech Institute
Phone: (+1) 781-972-5464
Email: clingham@healthtech.com

For sponsorship information, please contact:

Companies A-K
Jason Gerardi
Sr. Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-972-5452
Email: jgerardi@healthtech.com

Companies L-Z
Ashley Parsons
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-972-1340
Email: ashleyparsons@healthtech.com

Conference Programs

• Display of Biologics
• Engineering Antibodies
• Machine Learning Part 2

• Antibody-Based Therapies
• Emerging Targets & Approaches
• Membrane Protein Targets

• Safety & Efficacy of Bispecifics
• Advancing Bispecifics
• Engineering Bispecifics

• Tumour Microenvironment
• Innovations in CAR Therapy
• Next-Gen Immunotherapies

• Optimisation & Developability
• Analytical Characterisation
• Protein Stability & Formulation

• Cell Line Engineering
• Expression Platforms
• Protein Process Development

• Intro to Machine Learning
• Machine Learning: Part 1
• Machine Learning: Part 2

• Intro to Machine Learning
• Intro to Bispecific Antibodies
• Intro to Protein Engineering